| Mrs Michelle Giles-honore, APN | |
|
90 Washington St, # 305, East Orange, NJ 07017-1050 | |
| (973) 676-2492 | |
| (973) 676-5901 |
| Full Name | Mrs Michelle Giles-honore |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 10 Years |
| Location | 90 Washington St, East Orange, New Jersey |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023416898 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 26NJ00523400 (New Jersey) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ennoble Hc Nj Pc | 0345638185 | 26 |
| Salerno Medical Associates Llp | 3678676434 | 19 |
| Senior Healthcare Outreach Program | 5890893713 | 10 |
| Personal Np Services Llc | 9335455179 | 34 |
News Archive
AstraZeneca has announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for once- daily SEROQUEL XR (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of major depressive disorder (MDD) as monotherapy, adjunct therapy, and maintenance therapy in adult patients.
Tobira Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies for HIV, announced today that it has initiated a Phase IIb clinical trial for the CCR5/CCR2 inhibitor cenicriviroc (TBR-652).
Individuals younger than 50 who have been previously vaccinated do not appear to have a substantially different immune response to a half-dose of influenza vaccine than to a full dose, according to a report in the December 8/22 issue of Archives of Internal Medicine.
The findings indicate that given the lower vaccine efficacy against the SARS-CoV-2 delta variant, France may face a large epidemic wave infecting 25% of the general population even with a 95% vaccine coverage. This, in turn, could affect the healthcare system in terms of hospital bed occupancy. The study is currently available on the medRxiv* preprint server.
› Verified 1 days ago
| Entity Name | Salerno Medical Associates Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184766107 PECOS PAC ID: 3678676434 Enrollment ID: O20070315000195 |
News Archive
AstraZeneca has announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for once- daily SEROQUEL XR (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of major depressive disorder (MDD) as monotherapy, adjunct therapy, and maintenance therapy in adult patients.
Tobira Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies for HIV, announced today that it has initiated a Phase IIb clinical trial for the CCR5/CCR2 inhibitor cenicriviroc (TBR-652).
Individuals younger than 50 who have been previously vaccinated do not appear to have a substantially different immune response to a half-dose of influenza vaccine than to a full dose, according to a report in the December 8/22 issue of Archives of Internal Medicine.
The findings indicate that given the lower vaccine efficacy against the SARS-CoV-2 delta variant, France may face a large epidemic wave infecting 25% of the general population even with a 95% vaccine coverage. This, in turn, could affect the healthcare system in terms of hospital bed occupancy. The study is currently available on the medRxiv* preprint server.
› Verified 1 days ago
| Entity Name | Senior Healthcare Outreach Program |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588707954 PECOS PAC ID: 5890893713 Enrollment ID: O20070531000042 |
News Archive
AstraZeneca has announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for once- daily SEROQUEL XR (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of major depressive disorder (MDD) as monotherapy, adjunct therapy, and maintenance therapy in adult patients.
Tobira Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies for HIV, announced today that it has initiated a Phase IIb clinical trial for the CCR5/CCR2 inhibitor cenicriviroc (TBR-652).
Individuals younger than 50 who have been previously vaccinated do not appear to have a substantially different immune response to a half-dose of influenza vaccine than to a full dose, according to a report in the December 8/22 issue of Archives of Internal Medicine.
The findings indicate that given the lower vaccine efficacy against the SARS-CoV-2 delta variant, France may face a large epidemic wave infecting 25% of the general population even with a 95% vaccine coverage. This, in turn, could affect the healthcare system in terms of hospital bed occupancy. The study is currently available on the medRxiv* preprint server.
› Verified 1 days ago
| Entity Name | Passaic Medical Care Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184811390 PECOS PAC ID: 0446472955 Enrollment ID: O20141118002527 |
News Archive
AstraZeneca has announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for once- daily SEROQUEL XR (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of major depressive disorder (MDD) as monotherapy, adjunct therapy, and maintenance therapy in adult patients.
Tobira Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies for HIV, announced today that it has initiated a Phase IIb clinical trial for the CCR5/CCR2 inhibitor cenicriviroc (TBR-652).
Individuals younger than 50 who have been previously vaccinated do not appear to have a substantially different immune response to a half-dose of influenza vaccine than to a full dose, according to a report in the December 8/22 issue of Archives of Internal Medicine.
The findings indicate that given the lower vaccine efficacy against the SARS-CoV-2 delta variant, France may face a large epidemic wave infecting 25% of the general population even with a 95% vaccine coverage. This, in turn, could affect the healthcare system in terms of hospital bed occupancy. The study is currently available on the medRxiv* preprint server.
› Verified 1 days ago
| Entity Name | Personal Np Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649658105 PECOS PAC ID: 9335455179 Enrollment ID: O20150825003750 |
News Archive
AstraZeneca has announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for once- daily SEROQUEL XR (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of major depressive disorder (MDD) as monotherapy, adjunct therapy, and maintenance therapy in adult patients.
Tobira Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies for HIV, announced today that it has initiated a Phase IIb clinical trial for the CCR5/CCR2 inhibitor cenicriviroc (TBR-652).
Individuals younger than 50 who have been previously vaccinated do not appear to have a substantially different immune response to a half-dose of influenza vaccine than to a full dose, according to a report in the December 8/22 issue of Archives of Internal Medicine.
The findings indicate that given the lower vaccine efficacy against the SARS-CoV-2 delta variant, France may face a large epidemic wave infecting 25% of the general population even with a 95% vaccine coverage. This, in turn, could affect the healthcare system in terms of hospital bed occupancy. The study is currently available on the medRxiv* preprint server.
› Verified 1 days ago
| Entity Name | Metropolitan Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700442415 PECOS PAC ID: 1759716590 Enrollment ID: O20200124000387 |
News Archive
AstraZeneca has announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for once- daily SEROQUEL XR (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of major depressive disorder (MDD) as monotherapy, adjunct therapy, and maintenance therapy in adult patients.
Tobira Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies for HIV, announced today that it has initiated a Phase IIb clinical trial for the CCR5/CCR2 inhibitor cenicriviroc (TBR-652).
Individuals younger than 50 who have been previously vaccinated do not appear to have a substantially different immune response to a half-dose of influenza vaccine than to a full dose, according to a report in the December 8/22 issue of Archives of Internal Medicine.
The findings indicate that given the lower vaccine efficacy against the SARS-CoV-2 delta variant, France may face a large epidemic wave infecting 25% of the general population even with a 95% vaccine coverage. This, in turn, could affect the healthcare system in terms of hospital bed occupancy. The study is currently available on the medRxiv* preprint server.
› Verified 1 days ago
| Entity Name | Call To Care Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265063846 PECOS PAC ID: 0547699514 Enrollment ID: O20200327000076 |
News Archive
AstraZeneca has announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for once- daily SEROQUEL XR (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of major depressive disorder (MDD) as monotherapy, adjunct therapy, and maintenance therapy in adult patients.
Tobira Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies for HIV, announced today that it has initiated a Phase IIb clinical trial for the CCR5/CCR2 inhibitor cenicriviroc (TBR-652).
Individuals younger than 50 who have been previously vaccinated do not appear to have a substantially different immune response to a half-dose of influenza vaccine than to a full dose, according to a report in the December 8/22 issue of Archives of Internal Medicine.
The findings indicate that given the lower vaccine efficacy against the SARS-CoV-2 delta variant, France may face a large epidemic wave infecting 25% of the general population even with a 95% vaccine coverage. This, in turn, could affect the healthcare system in terms of hospital bed occupancy. The study is currently available on the medRxiv* preprint server.
› Verified 1 days ago
| Entity Name | Nj Covid Team Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841893856 PECOS PAC ID: 2163834813 Enrollment ID: O20201222000924 |
News Archive
AstraZeneca has announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for once- daily SEROQUEL XR (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of major depressive disorder (MDD) as monotherapy, adjunct therapy, and maintenance therapy in adult patients.
Tobira Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies for HIV, announced today that it has initiated a Phase IIb clinical trial for the CCR5/CCR2 inhibitor cenicriviroc (TBR-652).
Individuals younger than 50 who have been previously vaccinated do not appear to have a substantially different immune response to a half-dose of influenza vaccine than to a full dose, according to a report in the December 8/22 issue of Archives of Internal Medicine.
The findings indicate that given the lower vaccine efficacy against the SARS-CoV-2 delta variant, France may face a large epidemic wave infecting 25% of the general population even with a 95% vaccine coverage. This, in turn, could affect the healthcare system in terms of hospital bed occupancy. The study is currently available on the medRxiv* preprint server.
› Verified 1 days ago
| Entity Name | Ennoble Hc Nj Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306500764 PECOS PAC ID: 0345638185 Enrollment ID: O20211028000825 |
News Archive
AstraZeneca has announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for once- daily SEROQUEL XR (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of major depressive disorder (MDD) as monotherapy, adjunct therapy, and maintenance therapy in adult patients.
Tobira Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies for HIV, announced today that it has initiated a Phase IIb clinical trial for the CCR5/CCR2 inhibitor cenicriviroc (TBR-652).
Individuals younger than 50 who have been previously vaccinated do not appear to have a substantially different immune response to a half-dose of influenza vaccine than to a full dose, according to a report in the December 8/22 issue of Archives of Internal Medicine.
The findings indicate that given the lower vaccine efficacy against the SARS-CoV-2 delta variant, France may face a large epidemic wave infecting 25% of the general population even with a 95% vaccine coverage. This, in turn, could affect the healthcare system in terms of hospital bed occupancy. The study is currently available on the medRxiv* preprint server.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Michelle Giles-honore, APN 90 Washington St, # 305, East Orange, NJ 07017-1050 Ph: (973) 676-2492 | Mrs Michelle Giles-honore, APN 90 Washington St, # 305, East Orange, NJ 07017-1050 Ph: (973) 676-2492 |
News Archive
AstraZeneca has announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for once- daily SEROQUEL XR (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of major depressive disorder (MDD) as monotherapy, adjunct therapy, and maintenance therapy in adult patients.
Tobira Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies for HIV, announced today that it has initiated a Phase IIb clinical trial for the CCR5/CCR2 inhibitor cenicriviroc (TBR-652).
Individuals younger than 50 who have been previously vaccinated do not appear to have a substantially different immune response to a half-dose of influenza vaccine than to a full dose, according to a report in the December 8/22 issue of Archives of Internal Medicine.
The findings indicate that given the lower vaccine efficacy against the SARS-CoV-2 delta variant, France may face a large epidemic wave infecting 25% of the general population even with a 95% vaccine coverage. This, in turn, could affect the healthcare system in terms of hospital bed occupancy. The study is currently available on the medRxiv* preprint server.
› Verified 1 days ago
Miss Hana Michele Baron, NP, RN Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 385 Tremont Ave, East Orange, NJ 07018 Phone: 973-676-1000 | |
Mrs. Carla Francis, APN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 385 Tremont Ave, East Orange, NJ 07018 Phone: 973-676-1000 | |
Miss Adaugo Oriji, PNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 132 Halsted St, East Orange, NJ 07018 Phone: 973-674-0036 | |
Sanjaykumar Shah, APN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 310 Central Avenue, Suite 102, East Orange, NJ 07018 Phone: 973-395-1550 Fax: 973-395-1556 | |
Dr. Theresa Reed, DNP, APN, ENP,FNP-BC Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 385 Tremont Ave, East Orange, NJ 07018 Phone: 973-676-1000 Fax: 973-395-7135 | |
Ms. Janet Ellen Coley-lima, APN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 385 Tremont Avenue, Hbpc, Mail Code 11e-3, East Orange, NJ 07018 Phone: 973-676-1000 Fax: 973-395-7042 |